Fluorinov Pharma Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $31.7M
Latest Deal Amount

Fluorinov Pharma General Information

Description

Operator of a pharmaceutical company intended to develop fluorine-based novel, safer and more effective medicine. The company's services include developing small molecule product portfolio for Multiple Myeloma, Waldenström's Macroglobulinemia, Leukemia, Glioblastoma, Lung and Pancreatic Cancers and Central Nervous System disorders, enabling patients to avail therapeutics to treat and avoid cancer diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Primary Office
  • 101 College Street, MaRS Centre, South Tower
  • Suite 300, L-349
  • Toronto, Ontario M5G 1L7
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Fluorinov Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 27-Jan-2016 $31.7M 00.000 000.00 Completed Generating Revenue
3. Early Stage VC 07-Jan-2015 00.000 Completed Generating Revenue
2. Early Stage VC 07-Jun-2012 $1.47M $1.47M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2010 Completed Generating Revenue
To view Fluorinov Pharma’s complete valuation and funding history, request access »

Fluorinov Pharma Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
FACIT Venture Capital Minority 000 0000 000000 0
Ontario Institute for Cancer Research Not-For-Profit Venture Capital Minority 000 0000 000000 0
StandUp Ventures Venture Capital Minority 000 0000 000000 0
To view Fluorinov Pharma’s complete investors history, request access »